Hapharco J.s.c. Branch Pharmaceutical Import Profile — Vietnam (DGFT 2022–2026)

Name: Hapharco J.s.c. Branch Pharmaceutical Import Records from India — 3 Products, $1.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Hapharco J.s.c. Branch — Pharmaceutical Importer Profile (2026) | 3 Products, $1.4M Trade | TransData Nexus

Hapharco J.s.c. Branch

Pharmaceutical Importer · Vietnam · Antimalarial & Antiparasitic Focus · $1.4M Total Trade · DGFT Verified

Hapharco J.s.c. Branch is a pharmaceutical importer based in Vietnam with a total trade value of $1.4M across 3 products in 2 therapeutic categories. Based on 27 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Hapharco J.s.c. Branch sources from 5 verified Indian suppliers, with Sun Pharmaceutical Industries Limited accounting for 44.1% of imports.

Hapharco J.s.c. Branch — Import Portfolio & Supplier Network

Hapharco J.s.c. Branch import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Hapharco J.s.c. Branch?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sun Pharmaceutical Industries Limited	$1.2M	32	44.1%
Cadila Healthcare Limited	$789.8K	31	29.2%
Zydus Lifesciences Limited

What Formulations Does Hapharco J.s.c. Branch Import?

Formulation	Value	Ships
Encorate tabs sodium valproate	$200.0K	4
Ocid 20MG capsule omeprazole	$141.3K	4
Syndopa 275 tablets levodopa 250MG &	$100.0K	2
Hcq hydroxychloroquine sulphate USP 200MG 10 x	$100.0K	2
Chemodox 2MG ML 10ML injection doxorubicin hydrochloride liposome Pack 1 vial sap code	$100.0K	2
Pantocid i.v. injectionspantoprazole	$97.7K	4
Rocimus 0.01% w/w tacrolimus ointment	$91.6K	2
Noklot 75MG tablets clopidogrel	$83.1K	2
Amlodac 5MG tablets amlodipine	$77.7K	2
Formonide 200 inhaler budesonide &	$69.2K	3
Pantocid i.v. injectionspantoprazole	$68.7K	3
Sunpexitaz INJ 100MG 1s vl vn	$55.4K	2
Forair 250 salmeterol & fluticasone	$54.3K	3
Sunmedabon TAB 200/0.2MG 5x1s vn	$50.0K	1
Hcq hydroxychloroquine sulphate USP	$50.0K	1

Hapharco J.s.c. Branch imports 68 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Hydroxychloroquine	Antimalarial & Antiparasitic	$650.0K	13	0.3%	7
2	Chloroquine	Antimalarial & Antiparasitic	$450.0K	9	0.3%	10
3	Doxorubicin	Oncology	$250.0K	5	0.1%	14

Hapharco J.s.c. Branch imports 3 pharmaceutical products across 2 categories into Vietnam totaling $1.4M.

Hapharco J.s.c. Branch — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Hapharco J.S.C. Branch is a pharmaceutical importer and buyer based in Vietnam, operating as a branch of the Hanoi-based Hapharco Joint Stock Company. Established in 1998, the branch is located at 27B Nguyễn Đình Chiểu Street, District 1, Ho Chi Minh City. (thuvienphapluat.vn) Hapharco J.S.C. is a prominent entity in Vietnam's pharmaceutical sector, engaged in the importation, distribution, and marketing of a wide range of pharmaceutical products. The company plays a significant role in ensuring the availability of essential medications across the country, contributing to the healthcare system's efficiency and effectiveness.

2Distribution Network

Hapharco J.S.C. Branch operates a comprehensive distribution network within Vietnam, with its primary office situated in Ho Chi Minh City. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive import activities suggest a well-established infrastructure capable of supporting nationwide distribution. The branch's strategic location in Ho Chi Minh City facilitates efficient access to both domestic and international markets, enhancing its ability to meet the pharmaceutical needs of the Vietnamese population.

3Industry Role

As a pharmaceutical importer and buyer, Hapharco J.S.C. Branch serves as a critical intermediary in Vietnam's pharmaceutical supply chain. The branch is responsible for sourcing and importing a diverse array of pharmaceutical products, including finished formulations such as tablets, capsules, syrups, and injections. By facilitating the entry of these products into the Vietnamese market, Hapharco J.S.C. Branch ensures that healthcare providers have access to a wide range of medications necessary for patient care. This role underscores the branch's importance in maintaining the flow of essential pharmaceuticals within the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Hapharco J.s.c. Branch

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Hapharco J.S.C. Branch's sourcing strategy exhibits a high degree of concentration, with a total import value of $1.4 million USD from India across 27 shipments. The top three imported products—Hydroxychloroquine, Chloroquine, and Doxorubicin—account for the entire import portfolio, indicating a focused procurement approach. This concentration suggests a strategic choice to specialize in specific therapeutic areas, potentially leveraging established relationships with Indian suppliers. However, such dependency on a limited number of products and suppliers may pose risks related to supply chain disruptions or regulatory changes affecting these specific medications.

2Supply Chain Resilience

The resilience of Hapharco J.S.C. Branch's supply chain is closely tied to its reliance on a select group of Indian suppliers. The branch imports finished pharmaceutical formulations exclusively from India, with the top five suppliers being SUN PHARMACEUTICAL INDUSTRIES LIMITED, CADILA HEALTHCARE LIMITED, ZYDUS LIFESCIENCES LIMITED, THE MADRAS PHARMACEUTICALS, and GLAND PHARMA LIMITED. This concentrated supplier base may expose the branch to risks such as supply interruptions or quality issues from these manufacturers. Diversifying the supplier base and incorporating additional suppliers could enhance supply chain resilience and mitigate potential disruptions.

Importing Pharmaceuticals into Vietnam — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Vietnam

1Regulatory Authority & Framework

In Vietnam, the Drug Administration of Vietnam (DAV) is the primary regulatory authority overseeing the pharmaceutical sector. The importation and distribution of pharmaceutical products are governed by the Law on Pharmacy No. 105/2016/QH13, issued on April 6, 2016, and its subsequent amendments and supplements. These regulations outline the conditions for obtaining import licenses, drug registration, and the responsibilities of pharmaceutical businesses operating within the country. Compliance with these laws is mandatory for all entities involved in the pharmaceutical supply chain in Vietnam.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Vietnam are detailed in Decree No. 54/2017/ND-CP, issued on May 8, 2017. This decree specifies the conditions for obtaining import licenses, including the necessity for pharmaceutical products to be registered with the DAV and granted Market Authorization (MA) before distribution. Additionally, the Good Manufacturing Practice (GMP) certification of manufacturing facilities is a critical factor in the import approval process. Vietnam recognizes GMP certifications from reputable international standards, such as EU GMP, WHO GMP, and PIC/S, ensuring that imported pharmaceutical products meet high-quality standards.

Hapharco J.s.c. Branch — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Hapharco J.S.C. Branch's product strategy focuses on importing finished pharmaceutical formulations in the antimalarial, antiparasitic, and oncology therapeutic areas. This focus aligns with the significant public health needs in Vietnam, where diseases such as malaria and various cancers are prevalent. The branch's imports of Hydroxychloroquine and Chloroquine address the ongoing demand for antimalarial treatments, while Doxorubicin caters to the oncology sector. This strategic selection of products indicates a targeted approach to meet critical healthcare demands in the country.

2Sourcing Profile

Hapharco J.S.C. Branch's sourcing strategy is centered on importing generic drug formulations from India, a country known for its robust pharmaceutical manufacturing capabilities. The branch's preference for finished pharmaceutical products, rather than raw active pharmaceutical ingredients (APIs), suggests a focus on ready-to-market solutions. India's established reputation for producing high-quality generic medications aligns with the branch's procurement objectives, ensuring that imported products meet the necessary standards for distribution in Vietnam.

3Market Positioning

Seller's Guide — How to Become a Supplier to Hapharco J.s.c. Branch

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Hapharco J.S.C. Branch, particularly those offering high-quality generic formulations in the antimalarial, antiparasitic, and oncology therapeutic areas. The branch's concentrated sourcing pattern indicates a preference for specialized products, presenting an opportunity for suppliers to meet this demand. However, potential suppliers must be prepared to navigate Vietnam's regulatory landscape, ensuring compliance with import licensing requirements, GMP certifications, and quality standards to establish a successful partnership.

2Requirements & Qualifications

Indian exporters seeking to supply Hapharco J.S.C. Branch and the broader Vietnamese market must adhere to several requirements:

Import License: Obtain an import license from the Drug Administration of Vietnam (DAV), as stipulated by the Law on Pharmacy No. 105/2016/QH13.

Drug Registration: Ensure that pharmaceutical products are registered with the DAV and granted Market Authorization (MA) before distribution.

Frequently Asked Questions — Hapharco J.s.c. Branch

What products does Hapharco J.s.c. Branch import from India?

Hapharco J.s.c. Branch imports 3 pharmaceutical products across 2 categories. Top imports: Hydroxychloroquine ($650.0K), Chloroquine ($450.0K), Doxorubicin ($250.0K).

Who supplies pharmaceuticals to Hapharco J.s.c. Branch from India?

Hapharco J.s.c. Branch sources from 5 verified Indian suppliers. The primary supplier is Sun Pharmaceutical Industries Limited (44.1% of imports, $1.2M).

What is Hapharco J.s.c. Branch's total pharmaceutical import value?

Hapharco J.s.c. Branch's total pharmaceutical import value from India is $1.4M, based on 27 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Hapharco J.s.c. Branch focus on?

Hapharco J.s.c. Branch imports across 2 categories. The largest: Antimalarial & Antiparasitic (81.5%), Oncology (18.5%).

Get Full Hapharco J.s.c. Branch Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.